1. United Kingdom Stocks

  2. •

    Industrials

  3. •

    Industrial - Machinery
Graft Polymer (UK) Plc

Graft Polymer (UK) Plc

GPL.L
Graft Polymer (UK) PlcGB flagLondon Stock Exchange
0.17
GBp
-0.01
- -
3.79MMarket Cap
Graft Polymer (UK) Plc
GPL.L
(London Stock Exchange)

Recent

price

0.17

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2021
2022
2023
FRC
- -
- -
- -
- -
- -
0.01
0.01
Revenue per Share
- -
-0.01
-0.01
- -
- -
-0.03
-0.03
Basic EPS, GAAP
-0.01
-0.01
- -
- -
- -
-0.03
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
-0.01
-0.02
-0.02
- -
-0.06
-0.09
Book Value per Share
0.01
- -
- -
-0.01
- -
0.02
- -
Tangible Book Value per Share
104
104
104
104
- -
104
104
Basic Weighted Avg Shares
- -
- -
- -
1
- -
1
1
Sales/Revenue/Turnover
- -
-2,313.79
-140.61
-85
- -
-496.49
-376.49
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
-1
-1
- -
- -
-3
-3
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-2,424.14
-163.03
-86.73
- -
-499.08
-531.52
Profit Margin (%)
- -
- -
-1
-1
-2
2
- -
Working Capital
- -
- -
- -
- -
- -
- -
- -
LT Debt
3
2
2
1
1
5
2
Total Equity
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
63.93%
-55.51%
Free Cash Flow
- -
- -
-52.24%
Net Income, GAAP
- -
- -
15.34%
Sales/Revenue/Turnover
- -
- -
8.3%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
1
2023
- -
- -
- -
- -
1

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
-0.03
2023
- -
- -
- -
- -
-0.03

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Fujian Zitian Media Technology Co., Ltd. (300280.SZ)
Veloryx Ltd (VRYX.TA)
Shanghai Chuangli Group Co., Ltd. (603012.SS)
Great Computer Corp. (8047.TWO)
Shenyang Machine Tool Co., Ltd. (000410.SZ)
OC Oerlikon Corporation AG (OERL.SW)
Business
Graft Polymer (UK) Plc develops innovative polymer modification technologies and drug delivery systems for industrial and biopharma applications; its core offerings include grafted polymer modifiers, nano-structured and crosslinking polymer alloys such as GRAFTALLOY and GRAFTAMID, halogen-free fire retardants in liquid and solid forms, polymer-polymer nano-alloys for self-reinforcing composites, and bespoke drug delivery solutions through its GraftBio division, which holds HACCP certification for bio supplements and pharma vehicles. The company, founded in 2017 with headquarters in London and primary research and manufacturing operations in Slovenia, serves markets across Europe, targeting polymer producers, compounders, processors in sectors like automotive, packaging, construction, and biotechnology customers seeking enhanced performance, reduced raw material use, and improved chemical properties via proprietary techniques including grafting, solid-state melt extrusion, hot ozonolysis, and powder hybridization. Recent developments include plant expansion in Slovenia doubling capacity in 2023 to support larger mandates and cashflow growth; multiple research, development, and supply agreements in 2023 with partners such as FORPET BALTIC for recycled PET production, Empresas Vilher for modified polymers, and the Faculty of Polymer Technology Slovenj Gradec for polymer matrices in EU Horizon projects; a proposed acquisition of Awakn Life Sciences Corp announced in December 2024 to enter addiction and mental health therapeutics via AWKN-001 and AWKN-002 programs for alcohol use disorder; and a planned name change to Solvonis Therapeutics Plc pending shareholder approval at a general meeting.